BioStem Technologies, Inc.
BioStem Technologies, Inc. Fundamental Analysis
BioStem Technologies, Inc. (BSEM) shows moderate financial fundamentals with a PE ratio of -13.17, profit margin of -13.86%, and ROE of -14.25%. The company generates $0.0B in annual revenue with strong year-over-year growth of 17.09%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 22.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze BSEM's fundamental strength across five key dimensions:
Efficiency Score
WeakBSEM struggles to generate sufficient returns from assets.
Valuation Score
ExcellentBSEM trades at attractive valuation levels.
Growth Score
ModerateBSEM shows steady but slowing expansion.
Financial Health Score
ExcellentBSEM maintains a strong and stable balance sheet.
Profitability Score
WeakBSEM struggles to sustain strong margins.
Key Financial Metrics
Is BSEM Expensive or Cheap?
P/E Ratio
BSEM trades at -13.17 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, BSEM's PEG of 0.10 indicates potential undervaluation.
Price to Book
The market values BioStem Technologies, Inc. at 2.21 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -240.70 times EBITDA. This is generally considered low.
How Well Does BSEM Make Money?
Net Profit Margin
For every $100 in sales, BioStem Technologies, Inc. keeps $-13.86 as profit after all expenses.
Operating Margin
Core operations generate -1.45 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-14.25 in profit for every $100 of shareholder equity.
ROA
BioStem Technologies, Inc. generates $-13.15 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
BioStem Technologies, Inc. produces operating cash flow of $9.96M, showing steady but balanced cash generation.
Free Cash Flow
BioStem Technologies, Inc. generates strong free cash flow of $6.60M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.39 in free cash annually.
FCF Yield
BSEM converts 7.56% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-13.17
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.10
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.21
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.83
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.09
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.12
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.14
vs 25 benchmark
ROA
Return on assets percentage
-0.13
vs 25 benchmark
ROCE
Return on capital employed
-0.02
vs 25 benchmark
How BSEM Stacks Against Its Sector Peers
| Metric | BSEM Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -13.17 | 28.23 | Better (Cheaper) |
| ROE | -14.25% | 737.00% | Weak |
| Net Margin | -13.86% | -46175.00% (disorted) | Weak |
| Debt/Equity | 0.09 | 0.35 | Strong (Low Leverage) |
| Current Ratio | 4.12 | 4.10 | Strong Liquidity |
| ROA | -13.15% | -17785.00% (disorted) | Weak |
BSEM outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews BioStem Technologies, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
6386.31%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
382.33%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
1735.82%
Industry Style: Defensive, Growth, Innovation
High Growth